FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2011098322> ?p ?o ?g. }

• W2011098322 endingPage "709" @default.
• W2011098322 startingPage "705" @default.
• W2011098322 abstract "Although prostate-specific antigen (PSA) has become the reference standard for prostate cancer diagnosis, few reports have examined the long-term changes in PSA values before the diagnosis of prostate cancer in a large number of subjects. We investigated serial PSA levels and related values before prostate cancer diagnosis in a mass screening population and analyzed the values in an attempt to discover some values useful in clinical diagnostic science.We performed mass screening for prostate cancer in 9671 subjects from 1986 to 1998. The initial screening method was measurement of prostatic acid phosphatase from 1986 to 1991 and measurement of PSA from 1992 to 1998. As a result, 303 cases of prostate cancer were diagnosed. For all the cases diagnosed before 1991, we measured the serum PSA value in preserved frozen serum.The prostate cancer detection rate was 3.1% among all subjects observed during the 13-year period. By measurement of the PSA level using frozen serum during the pre-PSA era, we found that 62% of patients demonstrated a PSA abnormality for more than 1 year (average 2.8) before prostate cancer diagnosis. Prostate cancer that was diagnosed within 1 year after a PSA value became abnormal was not associated with bone metastasis. Concerning the relationship between PSA velocity (PSAV) and clinical stage, the proportion of Stage B cancer was 86% in the subjects whose PSAV level before diagnosis was 0.18 ng/mL/yr or less and it was only 29% in those with PSAV levels of 4.5 ng/mL/yr or more. Only 3 (3.5%) of 86 patients with prostate cancer with PSAV levels of 4.4 ng/mL/yr or less had bone metastasis, and 2 of those 3 patients had poorly differentiated adenocarcinoma.Although a total of 62% of patients had an abnormal PSA level more than 1 year before prostate cancer diagnosis, no patients with prostate cancer who were diagnosed within 1 year after the PSA level became abnormal had bone metastasis. Among patients who have undergone mass screening twice or more, a clinically useful indicator of the lack of bone metastasis would be a period between the detection of PSA levels of 4.1 ng/mL or more but not more than 10 ng/mL and prostate cancer diagnosis of less than 1 year and a diagnosis of well or moderately differentiated adenocarcinoma or a PSAV of 4.4 ng/mL/yr or less and a cancer diagnosis of well or moderately differentiated adenocarcinoma." @default.
• W2011098322 created "2016-06-24" @default.
• W2011098322 creator A5031697973 @default.
• W2011098322 creator A5035523996 @default.
• W2011098322 creator A5036226748 @default.
• W2011098322 creator A5046891404 @default.
• W2011098322 creator A5049978921 @default.
• W2011098322 creator A5070852103 @default.
• W2011098322 creator A5081728820 @default.
• W2011098322 creator A5085789327 @default.
• W2011098322 date "2000-05-01" @default.
• W2011098322 modified "2023-10-16" @default.
• W2011098322 title "Correlation of prostate-specific antigen before prostate cancer detection and clinicopathologic features: evaluation of mass screening populations" @default.
• W2011098322 cites W1258323304 @default.
• W2011098322 cites W1455378812 @default.
• W2011098322 cites W195741252 @default.
• W2011098322 cites W1975876685 @default.
• W2011098322 cites W1996368360 @default.
• W2011098322 cites W2008778834 @default.
• W2011098322 cites W2010117587 @default.
• W2011098322 cites W2042123453 @default.
• W2011098322 cites W2059250701 @default.
• W2011098322 cites W2409716152 @default.
• W2011098322 cites W2513575708 @default.
• W2011098322 cites W4236857774 @default.
• W2011098322 cites W4240477287 @default.
• W2011098322 cites W4248869731 @default.
• W2011098322 doi "https://doi.org/10.1016/s0090-4295(99)00568-3" @default.
• W2011098322 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10792085" @default.
• W2011098322 hasPublicationYear "2000" @default.
• W2011098322 type Work @default.
• W2011098322 sameAs 2011098322 @default.
• W2011098322 citedByCount "34" @default.
• W2011098322 countsByYear W20110983222012 @default.
• W2011098322 countsByYear W20110983222013 @default.
• W2011098322 countsByYear W20110983222016 @default.
• W2011098322 countsByYear W20110983222017 @default.
• W2011098322 countsByYear W20110983222018 @default.
• W2011098322 countsByYear W20110983222022 @default.
• W2011098322 crossrefType "journal-article" @default.
• W2011098322 hasAuthorship W2011098322A5031697973 @default.
• W2011098322 hasAuthorship W2011098322A5035523996 @default.
• W2011098322 hasAuthorship W2011098322A5036226748 @default.
• W2011098322 hasAuthorship W2011098322A5046891404 @default.
• W2011098322 hasAuthorship W2011098322A5049978921 @default.
• W2011098322 hasAuthorship W2011098322A5070852103 @default.
• W2011098322 hasAuthorship W2011098322A5081728820 @default.
• W2011098322 hasAuthorship W2011098322A5085789327 @default.
• W2011098322 hasConcept C121608353 @default.
• W2011098322 hasConcept C126322002 @default.
• W2011098322 hasConcept C126894567 @default.
• W2011098322 hasConcept C143998085 @default.
• W2011098322 hasConcept C146357865 @default.
• W2011098322 hasConcept C151730666 @default.
• W2011098322 hasConcept C2775941076 @default.
• W2011098322 hasConcept C2776235491 @default.
• W2011098322 hasConcept C2776490512 @default.
• W2011098322 hasConcept C2779013556 @default.
• W2011098322 hasConcept C2780192828 @default.
• W2011098322 hasConcept C2781406297 @default.
• W2011098322 hasConcept C2908647359 @default.
• W2011098322 hasConcept C29456083 @default.
• W2011098322 hasConcept C71924100 @default.
• W2011098322 hasConcept C86803240 @default.
• W2011098322 hasConcept C87874733 @default.
• W2011098322 hasConcept C99454951 @default.
• W2011098322 hasConceptScore W2011098322C121608353 @default.
• W2011098322 hasConceptScore W2011098322C126322002 @default.
• W2011098322 hasConceptScore W2011098322C126894567 @default.
• W2011098322 hasConceptScore W2011098322C143998085 @default.
• W2011098322 hasConceptScore W2011098322C146357865 @default.
• W2011098322 hasConceptScore W2011098322C151730666 @default.
• W2011098322 hasConceptScore W2011098322C2775941076 @default.
• W2011098322 hasConceptScore W2011098322C2776235491 @default.
• W2011098322 hasConceptScore W2011098322C2776490512 @default.
• W2011098322 hasConceptScore W2011098322C2779013556 @default.
• W2011098322 hasConceptScore W2011098322C2780192828 @default.
• W2011098322 hasConceptScore W2011098322C2781406297 @default.
• W2011098322 hasConceptScore W2011098322C2908647359 @default.
• W2011098322 hasConceptScore W2011098322C29456083 @default.
• W2011098322 hasConceptScore W2011098322C71924100 @default.
• W2011098322 hasConceptScore W2011098322C86803240 @default.
• W2011098322 hasConceptScore W2011098322C87874733 @default.
• W2011098322 hasConceptScore W2011098322C99454951 @default.
• W2011098322 hasIssue "5" @default.
• W2011098322 hasLocation W20110983221 @default.
• W2011098322 hasLocation W20110983222 @default.
• W2011098322 hasOpenAccess W2011098322 @default.
• W2011098322 hasPrimaryLocation W20110983221 @default.
• W2011098322 hasRelatedWork W1985438891 @default.
• W2011098322 hasRelatedWork W2049045266 @default.
• W2011098322 hasRelatedWork W2051326303 @default.
• W2011098322 hasRelatedWork W2088197194 @default.
• W2011098322 hasRelatedWork W2373651588 @default.
• W2011098322 hasRelatedWork W2417976536 @default.
• W2011098322 hasRelatedWork W2418121778 @default.
• W2011098322 hasRelatedWork W2897445903 @default.
• W2011098322 hasRelatedWork W3082324229 @default.

• next